TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes of Bevacizumab Added to Upfront Chemotherapy in Endometrial Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
J. Clin. Oncol 2022 Jun 03;[EPub Ahead of Print], KW Thiel, EJ Devor, VL Filiaci, D Mutch, K Moxley, A Alvarez Secord, KS Tewari, ME McDonald, C Mathews, C Cosgrove, S Dewdney, C Aghajanian, MI Samuelson, HA Lankes, RA Soslow, KK LeslieFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.